Compare Merck & Co., Inc. (MRK) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Consumer Staples Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $143.65 (market cap $351.28B), while Consumer Staples Select Sector SPDR Fund trades at $83.25 (market cap $13.50B). The key difference: Merck & Co., Inc. is far larger — about 26× Consumer Staples Select Sector SPDR Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| MRK | XLP | |
|---|---|---|
Market Cap | $351.28B | $13.50B |
Volume | 7,969,665 | 14,599,953 |
Sector | Health | — |
52-Week High | $156.43 | $90.00 |
52-Week Low | $82.49 | $75.61 |
Typical Hold Time | 98 Days | 72 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
XLP trades at $81.70, showing slight weakness with a 0.09% decline amid bearish technical signals. The ETF maintains strong analyst support with a 100% buy rating from 2 analysts, though technical indicators show moving averages and overall signals are bearish. Recent news highlights XLP's defensive characteristics and competitive expense ratio advantage over peers.
The consumer staples ETF offers defensive exposure during market volatility, supported by positive sector performance in 2026. Key risks include interest rate sensitivity and potential consumer spending slowdowns. Analyst consensus remains bullish despite technical headwinds, positioning XLP as a core defensive holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
